RESULT UPDATE

KEY DATA

Rating	BUY
Sector relative	Outperformer
Price (INR)	5,606
12 month price target (INR)	6,600
52 Week High/Low	6,789/4,149
Market cap (INR bn/USD bn)	877/10.1
Free float (%)	63.1
Avg. daily value traded (INR mn)	2,962.1

SHAREHOLDING PATTERN

	June-25	Mar-25	Dec-24
Promoter	30.56%	30.66%	30.66%
FII	24.19%	24.36%	24.75%
DII	27.78%	26.85%	26.26%
Pledge	0%	0%	0%

FINANCIALS (INR mn)				
Year to March	FY24A	FY25A	FY26E	FY27E
Revenue	98,216	119,387	142,236	169,244
EBITDA	17,243	20,581	25,646	30,452
Adjusted profit	11,421	14,001	17,442	21,335
Diluted EPS (INR)	75.1	90.7	112.6	137.7
EPS growth (%)	17.6	20.8	24.1	22.3
RoAE (%)	24.5	24.8	24.9	25.0
P/E (x)	74.6	61.8	49.8	40.7
EV/EBITDA (x)	49.3	41.3	33.2	27.6
Dividend yield (%)	0.5	0.6	0.5	0.6

CHANGE IN ESTIMATES

	Revised e	stimates	% Revi	sion
Year to March	FY26E	FY27E	FY26E	FY27E
Rev (USD mn)	1,649	1,957	-0.4%	-0.5%
EBIT	21,922	26,993	0.8%	0.9%
Adjusted profit	17,442	21,335	0.3%	-0.6%
Diluted EPS (INR)	112.6	137.7	-0.1%	-1.0%

PRICE PERFORMANCE



Solid growth; deal momentum picking up

Persistent (PSYS) posted solid Q1FY26 results. Revenue at USD390mn, 3.9% QoQ (+3.3% CC QoQ, +19% CC YoY), slightly missed our estimate of 3.5% CC QoQ. EBIT margin declined 10bp QoQ to 15.5%, in line with our estimate. TCV was strong at USD520.8mn, up +13% YoY.

PSYS reported solid growth again — slightly missing estimates mainly due to a planned project transition. The growth thesis remains intact and the solid TCV during the quarter also pacified a major concern. Management stays confident of achieving USD2bn revenue (19% CAGR) even amid the uncertain macro environment. We maintain FY26E/27E (< 1% change). We now value PSYS at 48x FY27 PE (earlier 45x). Retain 'BUY' with a TP of INR6,600 (earlier INR6,250).

BFSI led growth; strong TCV & ACV

Revenue surged +3.9% QoQ (+3.3% CC QoQ) to USD389.7mn. BFSI (+9% QoQ) led the growth followed by tech (+3.6% QoQ). Healthcare fell -1.9% QoQ primarily due to transition of some work from onsite to offshore in a larger account it is expected to start growing again from Q2 onwards. TCV came in decent at USD520.8mn, +13% YoY, with solid ACV at USD385mn, +14.2% YoY. By geography, Europe/India/North America grew +11.3%/ +9.4%/ +3% QoQ while RoW declined -19.2% QoQ.

Margins stable; Aiming for top quartile growth and USD2bn by FY27

EBIT margins came in at 15.5%, -10bp QoQ led by lower ESOP costs (+230bp) partially offset by absence of earn-out reversal (-60bps), transition from onsite of offsite and delayed ramp-up in some accounts (-100bps), higher amortization costs (-40bps) and FX impact (-40bps). The wage hike has been postponed by a quarter due to macro volatility while ESOP costs are likely to remain flat for FY26, before starting to reduce again in FY27. Net Headcount addition was 746 in Q1 along with several leadership changes while attrition rose to 13.9% (12.9% in Q4FY25), within management's comfortable range. Management highlighted a pivot to an AI-led, platform-driven strategy structured around two core areas. It continues to aspire for top quartile growth in FY26 and maintain its target of USD2bn revenue by FY27. It continues to expect all three verticals to grow in FY27, with BFSI leading the growth.

Valuations appear expensive – deserves growth premium

Persistent continues to deliver industry-leading growth (18.7% YoY in Q1FY26). Its FY27 revenue target of USD2bn alludes to strong CAGR of 19%. All along, its margins and cashflow remain robust. The stock is now trading at 40x P/E FY27 – which might appear expensive, but we find it justified given the 24% earnings CAGR anticipated over FY25-27E; retain 'BUY/SO'.

Financials

Year to March	Q1FY26	Q1FY25	% Change	Q4FY25	% Change
Net Revenue	33,336	27,372	21.8	32,421	2.8
EBITDA	6,116	4,552	34.4	5,844	4.7
Adjusted Profit	4,249	3,064	38.7	3,957	7.4
Diluted EPS (INR)	27.2	19.9	36.8	25.4	7.2

Vibhor Singhal VIBHOR.SINGHAL@nuvama.com Nikhil Choudhary Nikhil.Choudhary@nuvama.com Yukti Khemani Khemani.Yukti@nuvama.com

Financial Statements

Income Statement (INR mn)

Year to March	FY24A	FY25A	FY26E	FY27E
Total operating income	98,216	119,387	142,236	169,244
Cost of revenues	65,231	78,740	92,547	110,359
Gross Profit	32,985	40,647	49,689	58,885
SG&A	15,742	20,066	24,043	28,433
EBITDA	17,243	20,581	25,646	30,452
Depreciation	3,094	3,069	3,724	3,459
EBIT	14,149	17,512	21,922	26,993
Add: Other income	1,280	1,382	1,907	2,111
Profit before tax	14,962	18,223	23,144	28,447
Prov for tax	3,541	4,221	5,702	7,112
Less: Other adj	(486)	0	0	0
Reported profit	10,935	14,001	17,442	21,335
Less: Excp.item (net)	0	0	0	0
Adjusted profit	11,421	14,001	17,442	21,335
Diluted shares o/s	152	154	155	155
Adjusted diluted EPS	75.1	90.7	112.6	137.7
DPS (INR)	26.3	35.3	30.0	32.0
Tax rate (%)	23.7	23.2	24.6	25.0

Balance Sheet (INR mn)

Year to March	FY24A	FY25A	FY26E	FY27E
Share capital	770	779	782	782
Reserves	48,807	62,411	76,211	92,589
Shareholders funds	49,577	63,191	76,993	93,371
Minority interest	0	0	0	0
Borrowings	0	0	0	0
Trade payables	22,526	24,175	24,916	29,390
Other liabs & prov	0	0	0	0
Total liabilities	74,176	87,366	101,609	122,061
Net block	11,637	13,846	13,406	13,147
Intangible assets	0	0	0	0
Capital WIP	0	0	0	0
Total fixed assets	11,637	13,846	13,406	13,147
Non current inv	8,266	9,803	13,415	15,415
Cash/cash equivalent	6,625	6,744	4,866	15,478
Sundry debtors	17,491	19,142	26,879	32,144
Loans & advances	10,226	12,886	14,473	17,308
Other assets	7,556	10,582	14,109	14,109
Total assets	74,176	87,366	101,609	122,061

Important Ratios (%)

Year to March	FY24A	FY25A	FY26E	FY27E
Direct Cost (% of sales)	66.4	66.0	65.1	65.2
S&M expns (% of sales)	8.1	8.2	8.2	8.3
G&A expns (% of sales)	7.6	8.5	8.7	8.5
EBIT margin (%)	14.4	14.7	15.4	15.9
Net profit margin (%)	11.6	11.7	12.3	12.6
Revenue growth (% YoY)	17.6	21.6	19.1	19.0
EBIT growth (% YoY)	13.4	23.8	25.2	23.1
Adj. profit growth (%)	20.1	22.6	24.6	22.3

Free Cash Flow (INR mn)

	,			
Year to March	FY24A	FY25A	FY26E	FY27E
Reported profit	10,935	14,001	17,442	21,335
Add: Depreciation	3,094	3,069	3,724	3,459
Interest (net of tax)	0	0	0	0
Others	0	0	0	0
Less: Changes in WC	(8,643)	(7,675)	(12,210)	(3,624)
Operating cash flow	5,386	9,395	8,956	21,170
Less: Capex	1,660	(5,278)	(3,283)	(3,200)
Free cash flow	7,046	4,117	5,673	17,970

Assumptions (%)

Year to March	FY24A	FY25A	FY26E	FY27E
GDP (YoY %)	6.5	6.3	6.5	6.5
Repo rate (%)	6.5	5.3	5.3	5.3
USD/INR (average)	84.0	84.4	86.5	86.5
Depreciation	3.1	2.6	2.6	2.0
USD revenue (USD mn)	1,186.1	1,409.1	1,648.7	1,956.6
YoY growth (%)	14.5	18.8	17.0	18.7
CC YoY growth (%)	14.4	19.0	17.0	18.7
Tax rate as % of PBT	23.7	23.2	24.6	25.0
Capex (INR mn)	(1,659.8)	5,278.2	3,283.1	3,200.0

Key Ratios

Year to March	FY24A	FY25A	FY26E	FY27E
RoE (%)	24.5	24.8	24.9	25.0
RoCE (%)	26.1	25.7	25.6	25.6
Div Payout Ratio(%)	36.6	39.0	26.6	23.2
Working cap/Sales (%)	13	15	21	20
Receivable days	62	56	59	64
Asset Turnover Ratio	0.7	0.7	0.8	0.8
Current Ratio	1.9	2.0	2.4	2.7
Net debt/equity (x)	(0.1)	(0.1)	(0.1)	(0.2)

Valuation Metrics

Year to March	F	Y24A	FY25A	FY26E	FY27E
Diluted P/E (x)		74.6	61.8	49.8	40.7
Price/BV (x)		17.2	13.7	11.3	9.3
EV/EBITDA (x)		49.3	41.3	33.2	27.6
Dividend yield (%)		0.5	0.6	0.5	0.6

Source: Company and Nuvama estimates

Valuation Drivers

Year to March	FY24A	FY25A	FY26E	FY27E
EPS growth (%)	17.6	20.8	24.1	22.3
RoE (%)	24.5	24.8	24.9	25.0
EBITDA growth (%)	13.5	19.4	24.6	18.7
Payout ratio (%)	36.6	39.0	26.6	23.2

Q1FY26 conference call highlights

- Revenue grew 3.3% QoQ CC. Overall demand environment was slower with difficult macro. Any improvement in macro should help going ahead.
- Deal wins: TCV for the quarter stood at USD520.8mn with TCV of new bookings coming in at USD337mn. The ACV of this TCV is USD385.3mn, out of which the ACV from new bookings contributed USD211.8mn. Overall pipeline is strong. Revenue conversion is a factor of ACV booking and revenue recognition from long-term deals.
- Client metrics: In US dollar terms, Top five customers grew 22.8% YoY, Top 10 by 20.2%, Top 20 by 23.1%, Top 50 by 22.7%, and Top 100 by 22.4%. As you would notice, there is a secular increase in revenue across all categories in the Top 100 accounts.
- Geography: NA grew 17.4% YoY, Europe grew 37.5% YoY, India grew 18.3% YoY and ROW grew -1.7% YoY.
- Healthcare decline by 2.1% QoQ, this was primarily due to transition of revenue for one client from onshore to offshore. Management expect growth in Healthcare from next quarter onwards. PSYS have grown very well in largest customer and done vendor consolidation as well. Growth was impacted by offshoring of business.
- **EBIT margin** came in at 15.5%, -10bps QoQ, +150bps YoY. Lower Esop cost (+230bps), absence of earn-out reversal (-60bps), transition from onsite of offsite and delayed ramp-up in some of account (-100bps), higher amortization (-40bps), fx impact (-40bps). Wage hike is delayed due to macro concerns. ESOP cost will remain flat for next couple of quarter before reducing again.
- Al/GenAI: Working on two areas. 1) Al for Tech: Focusing on enhancing
 engineering productivity launched Sasva 3.0. 2) Al for business enabling
 enterprise to be Al ready, working with multiple Fortune 1000 companies to
 modernize their Al architecture.
- **Employee metrics:** Headcount increased by 746 QoQ. Attrition increase to 13.9% from 12.9% QoQ. Rajiv Naithani joined as Chief people officer, succeeding Yogesh Patgaonkar. Appointed Shimona Chadha as the new chief marketing officer.
- **Outlook:** Will continue to aspire for Top quartile growth in FY26. Management remain committed of achieving USD2bn in revenue by the end of FY27.

Exhibit 1: Financial snapshot INR mn)

Year to March	Q1FY26	Q4FY25	QoQ (%)	Q1FY25	YoY (%)	FY25	FY26E	FY27E
Total revenues	33,336	32,421	2.8	27,372	21.8	119,387	142,236	169,244
Direct cost	21,576	21,117	2.2	18,329	17.7	78,740	92,547	110,359
Gross profit	11,760	11,304	4.0	9,043	30.0	40,647	49,689	58,885
Selling & marketing exp	5,644	5,460	3.4	4,491	25.7	20,066	24,043	28,433
EBITDA	6,116	5,844	4.7	4,552	34.4	20,581	25,646	30,452
Depreciation	253	240	5.4	212	19.5	921	3,039	3,459
Amortisation	685	551	24.3	501	36.9	2,149	685	0
EBIT	5,178	5,053	2.5	3,840	34.8	17,512	21,922	26,993
Less: Interest expense	171	185		141		671	685	658
Foreign ex (loss) / gain	189	(154)	(222.3)	(7)	(2,684.9)	89	339	200
Other income	358	338	5.9	314	14.1	1,292	1,568	1,911
PBT	5,554	5,052	9.9	4,005	38.7	18,223	23,144	28,447
Tax	1,305	1,094	19.2	941	38.6	4,221	5,702	7,112
Reported profit	4,249	3,957	7.4	3,064	38.7	14,001	17,442	21,335
Adjusted profit	4,249	3,957	7.4	3,064	38.7	14,001	17,442	21,335
as % of net revenues								
Gross profit	35.3	34.9		33.0		34.0	34.9	34.8
Selling & marketing exp	16.9	16.8		16.4		16.8	16.9	16.8
Admin exp	0.0	0.0		0.0		0.0	0.0	0.0
EBITDA	0.8	0.7		0.8		0.8	2.1	2.0
EBIT	15.5	15.6		14.0		14.7	15.4	15.9
Reported net profit	12.7	12.2		11.2		11.7	12.3	12.6
Tax rate	23.5	21.7		23.5		23.2	24.6	25.0

Source: Company, Nuvama Research


Exhibit 2: Growth by business unit and geography

Segmental Performance	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26
Business Units (% YoY)									
BFSI	15.9%	12.4%	8.8%	7.6%	7.2%	15.5%	21.7%	27.0%	30.7%
Healthcare & Life Sciences	9.4%	11.8%	26.5%	39.1%	66.6%	70.6%	52.8%	33.6%	12.5%
Tech & Emerging Verticals	21.4%	16.3%	11.8%	6.4%	2.5%	-0.4%	3.3%	9.4%	14.0%
Geographies (% YoY)									
North Americas	18.3%	15.0%	17.5%	16.4%	18.2%	21.6%	21.0%	21.3%	17.4%
Europe	33.7%	30.6%	12.4%	-14.2%	-6.7%	-1.5%	10.4%	30.0%	37.0%
India	2.6%	-3.7%	-7.6%	14.4%	14.8%	12.3%	12.6%	11.1%	18.7%
RoW	-21.9%	14.1%	-0.5%	25.8%	64.4%	18.4%	62.6%	8.6%	-2.2%

Source: Company, Nuvama Research


Key charts

Exhibit 3: USD revenue growth (YoY)




Source: Company, Nuvama Research

Exhibit 5: TCV (USD mn)




Source: Company, Nuvama Research

Exhibit 7: Attrition




Source: Company, Nuvama Research

Exhibit 4: EBITDA margins




Source: Company, Nuvama Research

Exhibit 6: ACV (USD mn)



Source: Company, Nuvama Research

Exhibit 8: Revenue breakdown by vertical and geography



Source: Company, Nuvama Research

Company Description

Following its initial success as a boutique firm focused on database internals, Persistent transformed itself and thus emerged as one of the leading outsourced product development (OPD) companies in India. It has deep domain expertise and employs more than 21,000 highly skilled software professionals.

The company's expertise in software platforms complements its abilities to execute digital transformation projects at scale. It also has in-depth experience in the focused areas of software, hi-tech & emerging industries, BFSI and healthcare & life sciences.

Investment Theme

Persistent's digital engineering expertise, industry solutions and delivery excellence continue to be unique and recognized by advisor community. The recent strategic investments in DataGlove, Shree Partners, SCI. Sureline and Media Agility bolstered the capabilities in key hyperscalars domain. Record-TCV, -ACV and -headcount addition indicate strong growth ahead.

Persistent's 30 years of leadership in software engineering and digital transformation along with its expertise in this space with long-term relationships and service offerings augurs robust momentum ahead. Its differentiated Digital Engineering expertise, trusted delivery model, robust client relationships and strong partner ecosystem would continue to fuel growth.

In addition, the company is proactively working with clients to help them navigate and thrive in the precarious economic environment, leveraging technologies such as cloud, AI and automation.

Key Risks

- High sensitivity to USD
- Aggressive competition from captives and lack of pricing power
- High exposure to the US, Canada geographies and limited industry exposure

Additional Data

Management

0	
CEO	Sandeep Kalra
CFO	Vinit Teredesai
Chairman	Dr. Anand Deshpande
Other	
Auditor	Walker Chandiok & Co LLP

Recent Company Research

Date	Title	Price	Reco
24-Apr-25	Solid performance yet again; Result Update	5163	Buy
22-Jan-25	Continues to lead industry on growth; Result Update	6111	Buy
22-Oct-24	Growth momentum continues; Result Update	5158	Buy

Holdings – Top 10*

	% Holding		% Holding
Despande Anand	29.24	HDFC AMC	2.49
Motilal Oswal A	5.57	Kotak Mahindra	2.31
Kotak Mahindra	4.89	Fund Rock Manag	2.22
Vanguard Group	2.94	Nippon Life Ind	1.91
Blackrock Inc	2.75	Axis AMC	1.64

^{*}Latest public data

Recent Sector Research

Date	Name of Co./Sector	Title
22-Jul-25	Zensar Technologies Ltd	Solid results; valuations full; <i>Result Update</i>
17-Jul-25	LTIMindtree	Steady quarter; on the path to recovery; Result Update
16-Jul-25	Tech Mahindra	Weak macro to constrain margin expansion; Result Update

Rating and Daily Volume Interpretation



Source: Bloomberg, Nuvama research

Rating Rationale & Distribution: Nuvama Research

Rating	Expected absolute returns over 12 months	Rating Distribution
Buy	15%	202
Hold	<15% and >-5%	66
Reduce	<-5%	36

DISCLAIMER

Nuvama Wealth Management Limited (defined as "NWML" or "Research Entity") a company duly incorporated under the Companies Act, 1956 (CIN No L67110MH1993PLC344634) having its Registered office situated at 801-804, Wing A, Building No. 3, Inspire BKC, G Block, Bandra Kurla Complex, Bandra East, Mumbai – 400 051 is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, Investment Adviser, Research Analyst and other related activities. Name of Compliance/Grievance officer: Mr. Atul Bapna, E-mail address: compliance-officer.nwm@nuvama.com Contact details +91 (22) 6623 3478 Investor Grievance e-mail address- grievance.nwm@nuvama.com

This Report has been prepared by NWML in the capacity of a Research Analyst having SEBI Registration No.INH000011316 and Enlistment no. 5723 with BSE and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Securities as defined in clause (h) of section 2 of the Securities Contracts (Regulation) Act, 1956 includes Financial Instruments and Currency Derivatives. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in Securities referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. The investment discussed or views expressed may not be suitable for all investors.

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject NWML and associates, subsidiaries / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report in certain report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. NWML reserves the right to make modifications and alterations to this statement as may be required from time to time. NWML or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. NWML is committed to providing independent and transparent recommendation to its clients. Neither NWML nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future performance. The

NWML shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, break down of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of the NWML to present the data. In no event shall NWML be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the NWML through this report.

We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.

NWML and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the Securities, mentioned herein or (b) be engaged in any other transaction involving such Securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance. (c) NWML may have proprietary long/short position in the above mentioned scrip(s) and therefore should be considered as interested. (d) The views provided herein are general in nature and do not consider risk appetite or investment objective of any particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation or solicitation to do business with NWML (e) Registration granted by SEBI and certification from NISM in no way guarantee performance of NWML or provide any assurance of returns to investors and clients.

NWML or its associates may have received compensation from the subject company in the past 12 months. NWML or its associates may have managed or co-managed public offering of securities for the subject company in the past 12 months. NWML or its associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. NWML or its associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. NWML or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Research analyst or his/her relative or NWML's associates may have financial interest in the subject company. NWML and/or its Group Companies, their Directors, affiliates and/or employees may have interests/ positions, financial or otherwise in the Securities/Currencies and other investment products mentioned in this report. NWML, its associates, research analyst and his/her relative may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of public appearance.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs and Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Research analyst has served as an officer, director or employee of subject Company: No

NWML has financial interest in the subject companies: No

NWML's Associates may have actual / beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report.

Research analyst or his/her relative has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

NWML has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

Subject company may have been client during twelve months preceding the date of distribution of the research report.

There were no instances of non-compliance by NWML on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. A graph of daily closing prices of the securities is also available at www.nseindia.com

Analyst Certification:

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Additional Disclaimers

Disclaimer for U.S. Persons

This research report is a product of NWML, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by NWML only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, NWML has entered into an agreement with a U.S. registered broker-dealer, Nuvama Financial Services Inc. (formerly Edelweiss Financial Services Inc.) ("NFSI"). Transactions in securities discussed in this research report should be effected through NFSI.

Disclaimer for U.K. Persons

The contents of this research report have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA").

In the United Kingdom, this research report is being distributed only to and is directed only at (a) persons who have professional experience in matters relating to investments falling within Article 19(5) of the FSMA (Financial Promotion) Order 2005 (the "Order"); (b) persons falling within Article 49(2)(a) to (d) of the Order (including high net worth companies and unincorporated associations); and (c) any other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons").

This research report must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this research report relates is available only to relevant persons and will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this research report or any of its contents. This research report must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person.

Disclaimer for Canadian Persons

This research report is a product of NWML, which is the employer of the research analysts who have prepared the research report. The research analysts preparing the research report are resident outside the Canada and are not associated persons of any Canadian registered adviser and/or dealer and, therefore, the analysts are not subject to supervision by a Canadian registered adviser and/or dealer, and are not required to satisfy the regulatory licensing requirements of the Ontario Securities Commission, other Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and are not required to otherwise comply with Canadian rules or regulations regarding, among other things, the research analysts' business or relationship with a subject company or trading of securities by a research analyst.

This report is intended for distribution by NWML only to "Permitted Clients" (as defined in National Instrument 31-103 ("NI 31-103")) who are resident in the Province of Ontario, Canada (an "Ontario Permitted Client"). If the recipient of this report is not an Ontario Permitted Client, as specified above, then the recipient should not act upon this report and should return the report to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any Canadian person.

NWML is relying on an exemption from the adviser and/or dealer registration requirements under NI 31-103 available to certain international advisers and/or dealers. Please be advised that (i) NWML is not registered in the Province of Ontario to trade in securities; (ii) NWML's head office or principal place of business is located in India; (iii) all or substantially all of NWML's assets may be situated outside of Canada; (iv) there may be difficulty enforcing legal rights against NWML because of the above; and (v) the name and address of the NWML's agent for service of process in the Province of Ontario is: Bamac Services Inc., 181 Bay Street, Suite 2100, Toronto, Ontario MSJ 273 Canada.

Disclaimer for Singapore Persons

In Singapore, this report is being distributed by Nuvama Investment Advisors Private Limited (NIAPL) (Previously Edelweiss Investment Advisors Private Limited ("EIAPL")) (Co. Reg. No. 201016306H) which is a holder of a capital markets services license and an exempt financial adviser in Singapore and (ii) solely to persons who qualify as "institutional investors" or "accredited investors" as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Pursuant to regulations 33, 34, 35 and 36 of the Financial Advisers Regulations ("FAR"), sections 25, 27 and 36 of the Financial Advisers Act, Chapter 110 of Singapore shall not apply to NIAPL when providing any financial advisory services to an accredited investor (as defined in regulation 36 of the FAR. Persons in Singapore should contact NIAPL in respect of any matter arising from, or in connection with this publication/communication. This report is not suitable for private investors.

Disclaimer for Hong Kong persons

This report is distributed in Hong Kong by Nuvama Investment Advisors (Hong Kong) Private Limited (NIAHK) (Previously Edelweiss Securities (Hong Kong) Private Limited (ESHK)), a licensed corporation (BOM -874) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to Section 116(1) of the Securities and Futures Ordinance "SFO". This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The report also does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of any individual recipients. The Indian Analyst(s) who compile this report is/are not located in Hong Kong and is/are not licensed to carry on regulated activities in Hong Kong and does not / do not hold themselves out as being able to do so.

INVESTMENT IN SECURITIES MARKET ARE SUBJECT TO MARKET RISKS. READ ALL THE RELATED DOCUMENTS CAREFULLY BEFORE INVESTING.

Abneesh Roy Head of Research Committee Abneesh.Roy@nuvama.com